Good news! Botox move over! Unfortunately, this research is still early stage.
"... Using an old skin graft on young mice, they proved that it is possible to make skin and other organs young again via a change in molecular structure through all the layers of the skin. ...
Transplanting aged human skin onto young mice with severe combined immunodeficiency disease (SCID) that genetically affects both B and T lymphocytes can rejuvenate the transplantation of living cells, tissues or organs from one species to another, they wrote. This is accompanied by angiogenesis (the growth of new blood vessels), repigmentation of the epidermis (outer layer of the skin) and significant improvements in vital biomarkers connected to aging. ..."
From the abstract:
"Transplanting aged human skin onto young SCID/beige mice morphologically rejuvenates the xenotransplants. This is accompanied by angiogenesis, epidermal repigmentation, and substantial improvements in key aging-associated biomarkers, including ß-galactosidase, p16ink4a, SIRT1, PGC1α, collagen 17A, and MMP1. Angiogenesis- and hypoxia-related pathways, namely, vascular endothelial growth factor A (VEGF-A) and HIF1A, are most up-regulated in rejuvenated human skin. This rejuvenation cascade, which can be prevented by VEGF-A–neutralizing antibodies, appears to be initiated by murine VEGF-A, which then up-regulates VEGF-A expression/secretion within aged human skin. While intradermally injected VEGF-loaded nanoparticles suffice to induce a molecular rejuvenation signature in aged human skin on old mice, VEGF-A treatment improves key aging parameters also in isolated, organ-cultured aged human skin, i.e., in the absence of functional skin vasculature, neural, or murine host inputs. This identifies VEGF-A as the first pharmacologically pliable master pathway for human organ rejuvenation in vivo and demonstrates the potential of our humanized mouse model for clinically relevant aging research."
No comments:
Post a Comment